Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
Abstract Results from Blinded Buprenorphine OR Neonatal morphine solution (BBORN), a previous phase III trial in infants with neonatal opioid withdrawal syndrome (NOWS), demonstrated that sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than th...
Guardado en:
Autores principales: | Rena Eudy‐Byrne, Nicole Zane, Susan C. Adeniyi‐Jones, Marc R. Gastonguay, Ana Ruiz‐Garcia, Gagan Kushal, Walter K. Kraft |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/36acd5d7a6f74a369d135df943dae29b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Characterization of neonatal opioid withdrawal syndrome in Arizona from 2010-2017.
por: Emery R Eaves, et al.
Publicado: (2021) -
Metaheuristics for pharmacometrics
por: Seongho Kim, et al.
Publicado: (2021) -
Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
por: Michael Soyka
Publicado: (2021) -
Elucidating the context for implementing nonpharmacologic care for neonatal opioid withdrawal syndrome: a qualitative study of perinatal nurses
por: Clayton J. Shuman, et al.
Publicado: (2021) - CPT: Pharmacometrics & Systems Pharmacology